Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Arcutis Biotherapeutics Announces FDA Approval Of Supplemental New Drug Application For Zoryve (Roflumilast) Cream 0.15% To Treat Mild To Moderate Atopic Dermatitis In Adults And Children 6 And Older

Author: Benzinga Newsdesk | July 08, 2024 12:01pm

Posted In: ARQT